NICE u-turn on Novartis’ migraine drug Aimovig
New analyses submitted by Novartis has helped to secure a NICE recommendation for NHS funding
Read More
Tag: FAD
NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis
Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss.
Read More
NICE says no to expanding scope of Roche’s IPF drug
Patients in England and Wales with the lung scarring disease idiopathic pulmonary fibrosis will have to wait until their disease has worsened before getting routine NHS access to Roche’s Esbriet.
Read More
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
- Theolytics announces first patient dosed in the Octopod‑IP trial
- UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
- Saphnelo approved in the US for subcutaneous self‑administration
- Transgene completes randomisation in phase 2 trial of tg4050
